ceftaroline, Teflaro

 Indications

Acute bacterial skin/skin structure infections. Community-

acquired pneumonia.

Action

Binds to bacterial cell wall membrane, causing cell

death. Therapeutic Effects: Bactericidal action

against susceptible bacteria. Spectrum: Treatment

of skin/skin structure infections—Active against

Staphylococcus aureus (including methicillin-susceptible

and -resistant strains), Streptococcus pyogenes,

Streptococcus agalactiae, Escherichia coli, Klebsiella

pneumoniae, and Klebsiella oxytoca; Treatment of community acquired pneumonia—Streptococcus

pneumoniae (including pneumonia with bacteremia),

Staphylococcus aureus (methicillin-susceptible strains

only), Haemophilus influenzae, Klebsiella pneumoniae,

Klebsiella oxytoca, and Escherichia coli.

Pharmacokinetics

Absorption: IV administration results in complete

bioavailability of parent drug.

Distribution: Unknown.

Metabolism and Excretion: Ceftaroline fosamil is

rapidly converted by plasma phosphatases to ceftaroline,

the active metabolite; 88% excreted in urine, 6%

in feces.

Half-life: 2.6 hr (after multiple doses).

TIME/ACTION PROFILE (blood levels)

ROUTE ONSET PEAK DURATION

IV rapid end of infusion

12 hr

Contraindications/Precautions

Contraindicated in: Known serious hypersensitivity

to cephalosporins.

Use Cautiously in: Known hypersensitivity to other

beta-lactams; Renal impairment (dosageprequired for

CCr 50 mL/min); Geri: Dose adjustment may be necessary

for age-relatedpin renal function; OB: Use only

if potential benefit outweighs potential risk to fetus; Lactation:

Use cautiously if breast feeding; Pedi: Infants 2

mo (safety and effectiveness not established).

Adverse Reactions/Side Effects

GI: CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA

(CDAD), diarrhea, nausea. Derm: rash. Hemat: hemolytic

anemia. Local: phlebitis at injection site.

Misc: hypersensitivity reactions including ANAPHYLAXIS.

Interactions

Drug-Drug: None noted.

Route/Dosage

Acute Bacterial Skin/Skin Structure Infections

IV (Adults): 600 mg every 12 hr for 5–14 days.

IV (Children 2–17 yr and 33 kg): 400 mg every 8

hr or 600 mg every 12 hr.

IV (Children 2–17 yr and 33 kg): 12 mg/kg every

8 hr.

IV (Children 2 mo-2 yr): 8 mg/kg every 8 hr.

Renal Impairment

IV (Adults): CCr 30 to 50 mL/min—400 mg

every 12 hr; CCr 15 to 30 mL/min—300 mg every

12 hr; CCr 15 mL/min including hemodialysis—

200 mg every 12 hr.

Community-Acquired Pneumonia

IV (Adults): 600 mg every 12 hr for 5–7 days.

IV (Children 2–17 yr and 33 kg): 400 mg every 8

hr or 600 mg every 12 hr.

IV (Children 2–17 yr and 33 kg): 12 mg/kg every

8 hr.

IV (Children 2 mo-2 yr): 8 mg/kg every 8 hr.

Renal Impairment

IV (Adults): CCr 30 to 50 mL/min—400 mg

every 12 hr; CCr 15 to 30 mL/min—300 mg every

12 hr; CCr 15 mL/min including hemodialysis—

200 mg every 12 hr.

Availability

Powder for injection: 400 mg/vial, 600 mg/vial.